Back to List View Graph View

Dapagliflozin

Dapagliflozin is a small-molecule sodium-glucose cotransporter 2 (SGLT2) inhibitor used as a pharmacologic target in studies of diabetes and cardiorenal disease.

Where the papers sit

25 papers from the last 6 months study dapagliflozin directly · updated from PubMed 16 Nov 2026

  • SGLT2 Organ Protection

    SGLT2 inhibition is being pushed beyond glucose lowering toward tissue protection, especially in diabetic and transplant kidneys. Renal mechanisms recur around SLC5A2-SRC-ERK/STAT3, CTRP1-mediated glucotoxic stress, cellular senescence, AGE-RAGE signaling, and autophagy. Early work also tests effects on diabetic bone and lenses, cerebral ischemia, and post-hemorrhage hydrocephalus, while a transplant protocol addresses preservation prospectively. The breadth is promising, but several indications remain mechanistic, preclinical, or pilot-stage.

    10 papers · 40%

  • Type 2 Diabetes and Liver

    Type 2 diabetes treatment is moving toward comparative and combination strategies, with dapagliflozin tested against or alongside orforglipron, empagliflozin, DPP-4 inhibitors, and semaglutide. Glycemic control and adverse events remain core endpoints, while newer studies ask whether dapagliflozin improves hepatic steatosis, fibrosis, and insulin resistance. Mechanistic work attributes steatohepatitis benefit to restored Ca2+ homeostasis and hepatic insulin signaling. Direct comparisons and longer follow-up are still needed to separate glucose effects from liver-specific benefit.

    6 papers · 24%

  • Heart Failure Outcomes

    Heart-failure care is moving toward broader SGLT2 inhibitor use, with dapagliflozin and empagliflozin compared on cardiovascular events and uptake after guideline expansion. Pilot use in transthyretin cardiac amyloidosis targets symptoms, while cost-offset analyses test value in cardiovascular-kidney-metabolic disease. Preclinical work links dapagliflozin to altered cardiac protein profiles in long-standing type 1 diabetes. Whether benefits extend consistently across heart-failure phenotypes and amyloidosis remains open.

    5 papers · 20%

  • Diabetic Kidney Fibrosis

    Diabetic kidney disease work is converging on renal fibrosis, apoptosis, and mitochondrial quality control rather than glucose lowering alone. Dapagliflozin is being paired with exogenous klotho or liraglutide and linked to restored mitophagy, reduced apoptosis, and suppression of HO-1/TGF-β1/Smad2/3 signaling. These studies mainly rely on streptozotocin models or renal cells, so mechanistic support currently outweighs clinical evidence. A separate nanomicelle study extends dapagliflozin delivery to glaucoma, but does not alter the dominant kidney focus.

    4 papers · 16%

NEW DIRECTION

Dapagliflozin is introduced as an analytical measurement target rather than a therapeutic intervention

The first-derivative synchronous spectrofluorometric method for simultaneous determination of dapagliflozin and sitagliptin in dosage forms and spiked human plasma treats dapagliflozin not as a treatment or experimental disease-modifying intervention, as in the other studies, but as an analyte requiring selective quantification. The study develops and validates a spectrofluorometric assay that resolves dapagliflozin from sitagliptin without prior separation, establishing an analytical role for dapagliflozin outside the therapeutic and mechanistic categories used elsewhere in the set 42471380Jul.

dapagliflozin chemical structure

Papers

The 25 papers from the last 6 months that study dapagliflozin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

SGLT2 Organ Protection (10)
  1. Short- and long-term effects of dapagliflozin as an adjunct to insulin therapy in diabetic dogs: a pilot study. Veterinary research communications · 6 Nov 2026 PMID 42993417
  2. SGLT2 inhibition attenuates cytoskeletal and proteostatic dysfunction through the AGE-RAGE-IGFBP2-FBN1 signaling axis in diabetic lenses. European journal of pharmacology · 14 Aug 2026 PMID 42601001
  3. Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis. Calcified tissue international · 14 Aug 2026 PMID 42595915
  4. SGLT2 inhibitor alleviates hydrocephalus post intracerebral hemorrhage through enhancing autophagy via activating MEK/ERK pathway. Brain research bulletin · 12 Aug 2026 PMID 42586275
  5. SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes. Science translational medicine · 22 Jul 2026 PMID 42485434
  6. SGLT2 Inhibition Attenuates Renal Tubular Senescence by Suppressing CTRP1-Mediated Glucotoxic Stress in Diabetic Kidney Disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 16 Jul 2026 PMID 42461151
  7. Sex-specific responses in the early stages of diet-induced cardiovascular-kidney-metabolic syndrome. American journal of physiology. Heart and circulatory physiology · 7 Jul 2026 PMID 42411797
  8. SLC5A2-SRC-ERK/STAT3 signaling network in proximal tubule S1 cells mediates the renoprotective effects of dapagliflozin in obese mice. Biochemical and biophysical research communications · 27 Jun 2026 PMID 42364320
  9. Dapagliflozin pretreatment attenuates focal cerebral ischemia-reperfusion injury in rats. Molecular biology reports · 23 Jun 2026 PMID 42334656
  10. Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway-the DEAK study. BMJ open · 18 Jun 2026 PMID 42315275
Type 2 Diabetes and Liver (6)
  1. Dapagliflozin Ameliorates Steatohepatitis by Restoring Ca2+ Homeostasis and Hepatic Insulin Signaling. Diabetes & metabolism journal · 4 Nov 2026 PMID 42981857
  2. Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease. Medicine · 9 Oct 2026 PMID 42854065
  3. Efficacy of dapagliflozin on hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a pre-specified single-arm analysis from a randomized controlled trial. Diabetes research and clinical practice · 25 Aug 2026 PMID 42641810
  4. First-derivative synchronous spectrofluorimetric method for simultaneous determination of dapagliflozin and sitagliptin in dosage forms and spiked human plasma. Scientific reports · 18 Jul 2026 PMID 42471380
  5. Head-to-head comparative effectiveness of empagliflozin versus dapagliflozin and DPP-4 inhibitors on clinical and metabolic outcomes: a nationwide propensity-matched study. Scientific reports · 24 Jun 2026 PMID 42342812
  6. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. Lancet (London, England) · 8 Jun 2026 PMID 42259339
Heart Failure Outcomes (5)
  1. Using dapagliflozin to reduce symptoms in transthyretin cardiac amyloidosis: An n-of-1 trial series pilot study. PloS one · 7 Oct 2026 PMID 42842573
  2. Differential uptake of SGLT2 inhibitors in England following heart failure guideline expansion: a controlled interrupted time series analysis. BMJ open · 22 Sept 2026 PMID 42772884
  3. Effects of SGLT2 inhibitor dapagliflozin on the heart of rats with long-standing Type 1 diabetes mellitus: Protein profile. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 27 Jun 2026 PMID 42364425
  4. Comparative effectiveness of dapagliflozin vs. empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real-world prospective cohort study. British journal of clinical pharmacology · 26 Jun 2026 PMID 42357835
  5. Clinical events and healthcare costs of dapagliflozin in adults with cardiovascular-kidney-metabolic syndrome in Spain: a cost-offset analysis. Journal of medical economics · 25 Jun 2026 PMID 42343656
Diabetic Kidney Fibrosis (4)
  1. Dapagliflozin inhibits renal mesangial cell fibrosis by regulating HO-1/TGF-β1/Smad 2/3 axis. European journal of pharmacology · 10 Sept 2026 PMID 42722056
  2. Evaluation of the protective effects of liraglutide, dapagliflozin and their combination in rat kidneys of streptozotocin induced diabetes. Journal of diabetes and its complications · 24 Jun 2026 PMID 42341385
  3. Dapagliflozin embedded polymeric nanomicelles for enhanced ocular drug delivery: A promising strategy for glaucoma therapy. International journal of pharmaceutics · 22 Jun 2026 PMID 42331119
  4. Exogenous klotho as an adjunct to dapagliflozin ameliorates diabetic kidney disease by restoring mitophagy and mitigating apoptosis and fibrosis. Biochemical and biophysical research communications · 22 May 2026 PMID 42172900

By study type

Clinical trials (6)
  1. Using dapagliflozin to reduce symptoms in transthyretin cardiac amyloidosis: An n-of-1 trial series pilot study. PloS one · 7 Oct 2026 PMID 42842573
  2. Efficacy of dapagliflozin on hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a pre-specified single-arm analysis from a randomized controlled trial. Diabetes research and clinical practice · 25 Aug 2026 PMID 42641810
  3. Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis. Calcified tissue international · 14 Aug 2026 PMID 42595915
  4. SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes. Science translational medicine · 22 Jul 2026 PMID 42485434
  5. Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway-the DEAK study. BMJ open · 18 Jun 2026 PMID 42315275
  6. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. Lancet (London, England) · 8 Jun 2026 PMID 42259339
Observational studies and case reports (2)
  1. Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease. Medicine · 9 Oct 2026 PMID 42854065
  2. SGLT2 Inhibition Attenuates Renal Tubular Senescence by Suppressing CTRP1-Mediated Glucotoxic Stress in Diabetic Kidney Disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 16 Jul 2026 PMID 42461151
Human data, design not indexed (3)
  1. Differential uptake of SGLT2 inhibitors in England following heart failure guideline expansion: a controlled interrupted time series analysis. BMJ open · 22 Sept 2026 PMID 42772884
  2. First-derivative synchronous spectrofluorimetric method for simultaneous determination of dapagliflozin and sitagliptin in dosage forms and spiked human plasma. Scientific reports · 18 Jul 2026 PMID 42471380
  3. Clinical events and healthcare costs of dapagliflozin in adults with cardiovascular-kidney-metabolic syndrome in Spain: a cost-offset analysis. Journal of medical economics · 25 Jun 2026 PMID 42343656
Preclinical: animal, cell and lab studies (11)
  1. Short- and long-term effects of dapagliflozin as an adjunct to insulin therapy in diabetic dogs: a pilot study. Veterinary research communications · 6 Nov 2026 PMID 42993417
  2. Dapagliflozin inhibits renal mesangial cell fibrosis by regulating HO-1/TGF-β1/Smad 2/3 axis. European journal of pharmacology · 10 Sept 2026 PMID 42722056
  3. SGLT2 inhibition attenuates cytoskeletal and proteostatic dysfunction through the AGE-RAGE-IGFBP2-FBN1 signaling axis in diabetic lenses. European journal of pharmacology · 14 Aug 2026 PMID 42601001
  4. SGLT2 inhibitor alleviates hydrocephalus post intracerebral hemorrhage through enhancing autophagy via activating MEK/ERK pathway. Brain research bulletin · 12 Aug 2026 PMID 42586275
  5. Sex-specific responses in the early stages of diet-induced cardiovascular-kidney-metabolic syndrome. American journal of physiology. Heart and circulatory physiology · 7 Jul 2026 PMID 42411797
  6. Effects of SGLT2 inhibitor dapagliflozin on the heart of rats with long-standing Type 1 diabetes mellitus: Protein profile. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 27 Jun 2026 PMID 42364425
  7. SLC5A2-SRC-ERK/STAT3 signaling network in proximal tubule S1 cells mediates the renoprotective effects of dapagliflozin in obese mice. Biochemical and biophysical research communications · 27 Jun 2026 PMID 42364320
  8. Evaluation of the protective effects of liraglutide, dapagliflozin and their combination in rat kidneys of streptozotocin induced diabetes. Journal of diabetes and its complications · 24 Jun 2026 PMID 42341385
  9. Dapagliflozin pretreatment attenuates focal cerebral ischemia-reperfusion injury in rats. Molecular biology reports · 23 Jun 2026 PMID 42334656
  10. Dapagliflozin embedded polymeric nanomicelles for enhanced ocular drug delivery: A promising strategy for glaucoma therapy. International journal of pharmaceutics · 22 Jun 2026 PMID 42331119
  11. Exogenous klotho as an adjunct to dapagliflozin ameliorates diabetic kidney disease by restoring mitophagy and mitigating apoptosis and fibrosis. Biochemical and biophysical research communications · 22 May 2026 PMID 42172900
Unclassified: not yet indexed with MeSH (3)
  1. Dapagliflozin Ameliorates Steatohepatitis by Restoring Ca2+ Homeostasis and Hepatic Insulin Signaling. Diabetes & metabolism journal · 4 Nov 2026 PMID 42981857
  2. Comparative effectiveness of dapagliflozin vs. empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real-world prospective cohort study. British journal of clinical pharmacology · 26 Jun 2026 PMID 42357835
  3. Head-to-head comparative effectiveness of empagliflozin versus dapagliflozin and DPP-4 inhibitors on clinical and metabolic outcomes: a nationwide propensity-matched study. Scientific reports · 24 Jun 2026 PMID 42342812